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Introduction
The Salvador/Warts/Hippo (SWH) network was originally 
identified in D. melanogastor as a pathway responsible for regu-
lating cellular proliferation and apoptosis through upregulation 
of cyclin E, diap1 and bantam.1 The core components of the fly 
network, Hippo, Sav, Wts, Mats are conserved in mammals as 
MST1/2, WW45, LATS1/2 and MOB1. The core of the hippo 
pathway has been well studied.2 The sterile-20 kinase Hippo 
forms a complex with Salvador, a WW-repeat scaffolding pro-
tein. This in turn phosphorylates and activates the DBF fam-
ily kinase Warts. Activated Warts in association with MATS 
phosphorylates and inhibits the transcriptional co-activator 
Yorkie. This in turn leads to a reduction in cell number owing 
to the downregulation of transcriptional targets of Yorkie, the 
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anti-apoptotic molecules diap1 and the microRNA bantam and 
the cell cycle regulator cyclin E. Hence the SWH pathway activa-
tion leads to smaller organs with fewer cells, and the reverse hap-
pens, increase in cell number and tissue size when the pathway 
is downregulated. Upstream components of the pathway include 
Merlin and Expanded. Very recently three groups identified the 
WW-domain containing protein Kibra as an upstream compo-
nent of the SWH pathway and demonstrated that it acts as a 
tumor suppressor gene in Drosophila.3-5
RASSF1A tumor suppressor gene belongs to a family of 
proteins containing a RAS-association domain in either their 
C (RASSF1-RASSF6) or N-terminals (RASSF7-RASSF10).6-8 
It has been demonstrated that in mammalian cells RASSF1A 
forms a complex similar to the SWH network in Drosophila.9 
RASSF1A interacts with MST1 and MST2 and this binding 
The WW-domain containing protein KIBRA has recently been identified as a new member of the Salvador/Warts/Hippo 
(SWH) pathway in Drosophila and is shown to act as a tumor suppressor gene in Drosophila. This pathway is conserved 
in humans and members of the pathway have been shown to act as tumor suppressor genes in mammalian systems. We 
determined the methylation status of the 5' CpG island associated with the KIBRA gene in human cancers. In a large panel 
of cancer cell lines representing common epithelial cancers KIBRA was unmethylated. But in pediatric acute lymphocytic 
leukemia (ALL) cell lines KIBRA showed frequent hypermethylation and silencing of gene expression, which could be 
reversed by treatment with 5-aza-2'-deoxycytidine. In ALL patient samples KIBRA was methylated in 70% B-ALL but was 
methylated in <20% T-ALL leukemia (p = 0.0019). In B-ALL KIBRA methylation was associated with ETV6/RUNX1 [t(12;21)
(p13;q22)] chromosomal translocation (p = 0.0082) phenotype, suggesting that KIBRA may play an important role in 
t(12;21) leukemogenesis. In ALL paired samples at diagnosis and remission KIBRA methylation was seen in diagnostic but 
not in any of the remission samples accompanied by loss of KIBRA expression in disease state compared to patients in 
remission. Hence KIBRA methylation occurs frequently in B-cell acute lymphocytic leukemia but not in epithelial cancers 
and is linked to specific genetic event in B-ALL.
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Methylation and expression analysis in leukemia cell lines. 
We next examined a panel of acute lymphocytic leukemia cell 
lines for KIBRA methylation. Among six cell lines, three were 
completely and one was partially methylated for KIBRA and two 
cell lines were unmethylated (Fig. 1A). In order to demonstrate 
biological significance of this methylation, the leukemia cell lines 
were treated with 5-aza-2'-deoxycytidine. KIBRA gene expres-
sion could be seen after 5-aza-2'-deoxycytidine treatment in the 
methylated cell lines, while no change was seen in unmethylated 
lines (Fig. 1B).
Methylation analysis in primary ALL leukemia samples. In 
acute lymphocytic leukemia KIBRA methylation was detected 
in 33/47 (70%) B-cell ALL and much less frequently in T-cell 
ALL, 2/12 (16.7%) (Fig. 2A and B) (p = 0.0019). In order to 
confirm the COBRA results and to determine the extent and 
pattern of KIBRA CpG island methylation, we sequenced the 
DNA from bisulfite-modified ALL samples. As seen in Figure 
3 the CpG region analyzed was heavily methylated throughout 
giving high values for the methylation index (MI). No methyla-
tion was detected in DNA from age matched peripheral blood 
lymphocytes from healthy individuals or in healthy bone mar-
row (Fig. 3). In B-cell ALL patient samples KIBRA methyla-
tion was strongly associated with ETV6/RUNX1 translocation 
(p = 0.0082), the most common translocation occurring in this 
leukemia sub-type. Our data suggests that KIBRA may play an 
important role in t(12;21) leukemogenesis. Survival analysis 
was not possible in the ALL cohort since very few individuals 
is important for some of its functional properties.10-12 We pre-
viously undertook a methylation screen of all RASSF mem-
bers (RASSF1A-RASSF10) in acute lymphocytic leukemia. We 
demonstrated that RASSF6 and RASSF10 were the only mem-
bers that were frequently and specifically methylated in ALL. 
RASSF6 was very frequently methylated in B-ALL (94%) and in 
41% T-ALL, while RASSF10 was frequently methylated in 88% 
T-ALL but showed <20% methylation in B-ALL.13 In this report 
we demonstrate that the latest member of the SWH pathway, 
KIBRA is frequently methylated in B-ALL and this methylation 
is associated with the most common genetic event occurring in 
B-ALL.
Results
Methylation analysis in common epithelial cancers. A large 
panel of tumor cell lines (n = 49) consisting of major epithelial 
cancers was analyzed for methylation in the 5'CpG island asso-
ciated with the KIBRA gene. We designed primers encompass-
ing part of the KIBRA 5'CpG island and used COBRA assay 
to detect methylation. The cell line panel consisted of breast, 
colorectal, glioma, kidney, lung and prostate cancer cell lines. 
One out of seven glioma cell lines showed partial methylation, 
rest of the cancer cell lines in the panel showed no methylation 
(Sup. Fig. S1). We went on to analyze 20 glioma tumors, KIBRA 
was unmethylated in all cases (Sup. Fig. S1). Hence KIBRA is 
unmethylated in these epithelial cancers.
Figure 1. Leukemia cell line methylation and expression status. KIBRA methylation and re-expression in leukemia cell lines. (A) Undigested PCR prod-
uct (U) is shown next to digested PCR product (D) for three leukemia cell lines, one normal bone marrow sample and two normal blood samples.  
(B) GAPDH and KIBRA RT-PCR results are shown for unmethylated cell line THP-1, partially methylated cell line U937 and completely methylated cell 
line SUP-T1 pre (-) and post (+) treatment with 5-aza-2'-deoxycitidine. * indicates methylated samples.
328 Epigenetics Volume 6 Issue 3
hypermethylated genes in acute lymphocytic leukemia.17-19 Our 
laboratory recently carried out a comprehensive analysis of all 
RASSF gene family members (RASSF1-RASSF10) with an asso-
ciated 5' CpG island in acute lymphocytic leukemia. We demon-
strated that RASSF6 was the most frequently methylated family 
member in B-cell ALL (94%), while the newly characterized 
RASSF10 was most frequently methylated in T-cell ALL (88%).13 
RASSF1A has recently been linked with a highly conserved path-
way between Drosophila and mammals, Salvador-Warts-Hippo 
(SWH) tumor suppressor network. RASSF1A binds to a core 
component of the pathway, MST1 and MST2 (Hippo in 
Drosophila) and the subsequent biological role of this association 
has been determined in various cellular contexts.10,11,20,21 The SWH 
pathway was originally identified in the fly to control organ size. 
The core components of the pathway (Hippo, Salvador, Warts/
Lats, Mats, Yorkie and very recently Kibra) are evolutionally con-
served in mammals (MST1 and 2, SAV1, LATS1 and 2, MOB1, 
YAP and KIBRA). Recent studies have demonstrated a key role 
for the SWH pathway in regulating cell contact inhibition, 
organ size control and development of cancer in mammals.22-26 
Kibra was recently identified as upstream member of this path-
way and a potential tumor suppressor in Drosophila. Human 
KIBRA has been reported to play a role in cell migration and is 
known to be phosphorylated by protein kinase C (PKC) zeta.27-29
MSTs and LATs members of the SWH pathway have pre-
viously been shown to be epigenetically inactivated in certain 
human cancers. Frequent methylation of MST2 (96%) was 
found in head and neck squamous cell carcinoma and less fre-
quently for LATS1 (24%) and LATS2 (8%).30 MST1 and MST2 
were also methylated in soft tissue sarcomas.31 LATS1 and 
LATS2 were frequently methylated in human astrocytomas and 
in breast cancer.32,33 LATS2 was also methylated in 24% of acute 
lymphocytic leukemia.34 A very recent study highlighted the 
importance of the hippo signaling in the pathogenesis of B-cell 
underwent relapse. We also analyzed other members of the SWH 
pathway (FAT1, LATS1 and LATS2, MOBs, MST1 and MST2 
and SAV1) for epigenetic inactivation in acute lymphocytic leuke-
mia. Only FAT1 was found to be frequently methylated in B-ALL 
(65%) and less so in T-ALL (25%) (Sup. Figs. 2 and 3). FAT1 meth-
ylation in B-ALL associated with ETV6/RUNX1 translocation 
(p < 0.05).
Methylation and expression analysis in paired ALL samples 
at diagnosis and remission. We analyzed five paired ALL sam-
ples with the ETV6/RUNX1 translocation for KIBRA methyla-
tion in matched DNA at diagnosis and in remission. KIBRA was 
methylated in all five diagnostic samples but was unmethylated 
in all five matched remission samples (Fig. 4A). This provides 
further evidence that KIBRA methylation is cancer specific and 
is associated with the malignant state. We also examined KIBRA 
expression in the above matched samples. KIBRA expression 
was reduced or absent in the disease state compared to patients 
in remission (Fig. 4B). Hence loss of KIBRA is highly associ-
ated with the disease state in these patients and is biologically 
relevant.
Discussion
Acute lymphocytic leukemia is the most common form of child-
hood leukemia in the western World. ALL is characterized by 
specific translocations, including the most common transloca-
tion ETV6/RUNX1 [t(12;21)(p13;q22)], occurring in approxi-
mately 50% of childhood cases. ETV6/RUNX1 translocation is 
associated with good prognosis in individuals with this disease.14 
Aberrant DNA methylation has been well documented for epi-
thelial and hematological cancers and shown to play a strong role 
in tumorigenesis. Hypermethylation of tumor suppressor gene 
promoters are a well characterized hallmark of many cancers.15,16 
There have been several recent genome-wide studies to identify 
Figure 2. KIBRA methylation in ALL samples. CoBRA results are shown for six childhood B-ALL samples (A) and six childhood T-ALL samples (B).  
Undigested products (U) are shown next to BstUI digested products (D) for each sample. * indicates methylated samples.
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MOBKL2B and LATS2 was associated with inferior survival in 
mantle cell lymphoma (MCL); furthermore, loss of the genomic 
regions where the three genes reside was observed in 38% of 
lymphomas and demonstrated for the first time the Hippo path-
way as tumor suppressor genes contributing to lymphoma tumor-
igenesis.35 Decreased expression of Hippo members MOBKL2A, 
Figure 3. Sequencing of ALL samples and control blood and bone marrow. A schematic of the CpG island encompassing the first exon of KIBRA is 
shown with the CpG island in light grey, exon 1 in dark grey and the region analyzed for methylation by CoBRA and clone sequencing represented by 
dashed lines. Clone sequencing results are shown for four childhood B-ALL samples (B-ALL15, B-ALL9, B-ALL34 and B-ALL10), one normal blood sample 
and one normal bone marrow sample. Black circles represent methylated CpGs and white circles represent unmethylated CpGs. The methylation 
index (MI) is given as a percentage for each sample.
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childhood are required for leukemogenesis, one such mechanism 
could be epigenetic inactivation.
Our results further indicate that KIBRA is a potential tumor 
suppressor gene not only in Drosophila but also in mammalian 
cells and plays an important role in B-cell leukemogenesis and 
may provide a potential new therapeutic target for clinical appli-
cations especially due to the reversible nature of promoter hyper-
methylation. It will be interesting to see if KIBRA is methylated 
in other B-cell leukemias and lymphomas and to understand 
what role does KIBRA play in B-cell development/differentia-
tion. Our results add further evidence of the Hippo tumor sup-
pressor pathway dysregulation in hematological cancers.
Materials and Methods
Cell lines and primary patient samples. A panel of 49 epithe-
lial cancer cell lines (five breast, seven colorectal, seven glioma, 
ten kidney, 15 lung and five prostate) and seven leukemia cell 
lines were used for initial analysis [Jurkat (JKT), NALM6, U937, 
SUP-T1, CCRF-CEM (CEM), DND-41 and THP-1], in addi-
tion 20 glioma tumors were also analyzed. A total of 70 childhood 
ALL samples were used comprising 52 B-ALL, 1 pre-B-ALL, 12 
T-ALL and five unclassified. Characteristics of the ALL samples 
have been described previously in reference 17. Five diagnosis 
and remission paired samples were also used for childhood ALL 
MCLs. MOBKL2A and MOBKL2B are homologs of the MOB1 
gene that interacts with LATS in inhibition of YAP, a growth 
promoter.
There has been no comprehensive analysis of the SWH path-
way genes in both epithelial and hematological malignancies. 
Therefore, we have undertaken a detailed epigenetic analysis of 
KIBRA a newly identified member of the SWH pathway in both 
epithelial and hematological cancers. We describe for the first 
time frequent methylation of KIBRA in B-cell ALL, but not in 
major epithelial cancers. KIBRA gene methylation in childhood 
B-cell ALL is associated with the most common translocation 
(ETV6/RUNX1) found in this subtype of leukemia and leads to 
loss of KIBRA expression in the malignant state. Roman-Gomez 
et al. have previously shown that a set of four genes (DKK3, 
sFRP2, PTEN and P73) show methylation specificity for ETV6/
RUNX1 positive B-ALL and suggest that these genes may play 
important roles in t(12;21) leukemogenesis. Furthermore they 
demonstrated that patients carrying the ETV6/RUNX1 translo-
cation showed a higher degree of genes simultaneously methyl-
ated compared to ETV6/RUNX1 negative cases.36 This suggests 
that epigenetic inactivation plays a more important role in 
t(12;21) leukemogenesis compared to other forms of B-ALL. 
Morrow et al. demonstrated that ETV6/RUNX1 translocation is 
necessary but insufficient for leukemia development.37 The above 
data suggests that subsequent molecular events occurring in early 
Figure 4. Paired diagnosis and remission analysis. (A) CoBRA results are shown for five childhood ALL patients at diagnosis and remission stages of 
disease. All samples are shown with undigested product (U) next to digested product (D). (B) Expression results are shown for three of the five patients 
shown in (A) at diagnosis and remission stages of disease for KIBRA and GAPDH.
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HEPES, 1 mM sodium pyruvate, 12.6 mM glucose monohydrate 
at 37°C, 5% CO
2
. Genome demethylation was achieved by treat-
ment with 5 μM 5-aza-2'-deoxycitidine over five days with daily 
media changes. RNA-bee (AMS biotechnology) was used to 
extract RNA according to manufacturers’ instructions. Control 
bone marrow RNA was purchased from AMS biotechnology. 
cDNA was synthesized from 1 μg total RNA using Superscript 
III (Invitrogen) and random hexamer primers (Fermentas). 
Expression was assessed using a touchdown PCR with a total 
cycle number of 40 and final annealing temperature of 56°C 
using the following primers: F: 5'-AAA CAG AGC AGG GAG 
CTC AA-3' and R: 5'-CCC ATC CAT ATC AGG TGA GG-3'. 
GAPDH analysis was carried out concurrently with a lower cycle 
number (32 instead of 40) using the forward primer: 5'-TGA 
AGG TCG GAG TCA ACG-3' and reverse primer: 5'-CAT 
GTG GGC CAT GAG GTC C-3'.
Statistical analysis. Statistical analysis was performed as indi-
cated. p < 0.05 was considered significant.
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methylation and expression analyses. Ethical guidelines were fol-
lowed for all collected samples.
Methylation analysis. DNA was bisulfite-modified as 
described previously in reference 38. We analyzed a 368 bp 
region of the KIBRA CpG island just upstream of the transcrip-
tion start site using the following semi-nested primers, forward: 
5'-GTA TTT GGY GGA GGT AGA AGT TAT AAA TT-3', 
reverse nested: 5'-CAT AAT CCR AAA AAT AAC RCC CRC 
AAA TAA-3' and reverse: 5'-TAT CCC RCR AAT CRA CCA 
ACT AAT AAT A-3'. Primary and secondary PCR reactions 
were touchdown PCRs with a final annealing temperature of 
55°C and total cycle number of 42 and 47 respectively with 
5 μl primary PCR product transferred to the secondary reaction. 
15–20 μl of PCR product was digested with BstUI (CGCG) at 
37°C overnight prior to visualization on a 2% agarose gel.
Clone sequencing was used to quantify selected CoBRA 
results. Selected PCR products were cloned into the pGEM-T-
Easy vector according to manufacturers’ instructions. Single 
colony PCR was carried out on up to 12 colonies for each cloned 
sample using the following forward primer: 5'-TAA TAC GAC 
TCA CTA TAG GG-3'; and reverse primer: 5'-ACA CTA TAG 
AAT ACT CAA GC-3'. PCR products were then sequenced and 
methylation indexes (MIs) calculated for each sample as a per-
centage of the number of methylated CpGs out of the total num-
ber of CpGs analyzed per sample.
Expression analysis. Leukemia cell lines were maintained in 
RPMI1640 (Sigma) with 10% FCS, 2 mM glutamine, 20 mM 
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